CAPA within the Pharmaceutical Quality System

Martin VanTrieste, R.Ph
SVP Amgen

ICH Q10 Conference
October 4-6, 2011 – Arlington, Virginia
November 14-16, 2011 – Brussels, Belgium

Agenda

- What is CAPA?
- Other Industries
- Case Study:	How CAPA developed in Biotech
- The Desired State
- Enablers for an Effective CAPA System
- Lessons Learned
- Summary
What is CAPA per ICH Q10?
(Corrective and Preventive Actions)

A structured approach to the investigation process should be used with the objective of determining the root cause.

The level of effort, formality, and documentation of the investigation should be commensurate with the level of risk, in line with ICH Q9.

CAPA methodology should result in product and process improvements and enhanced product and process understanding.

Q10 Definition for Corrective Action

- **Corrective Action:** Action to eliminate the cause of a detected nonconformity or other undesirable situation.

  NOTE: Corrective action is taken to prevent recurrence whereas preventive action is taken to prevent occurrence. (ISO 9000:2005)
Q10 Definition for Preventive Action

- **Preventive Action**: Action to eliminate the cause of a potential nonconformity or other undesirable potential situation.

  NOTE: Preventive action is taken to prevent occurrence whereas corrective action is taken to prevent recurrence. (ISO 9000:2005)

A mature quality system detects problems before they occur and then prevents the problems

---

Agenda

- What is CAPA?
- Other Industries
- Case Study: How CAPA developed in Biotech
- The Desired State
- Enablers for an Effective CAPA System
- Lessons Learned
- Summary
Electronics Industry Challenges Drove Continuous Improvement

- Extreme cost pressures
- Product and designs are easy to copy
- Material & capital costs
- Consumers demand reliability

... Adopted six sigma to meet these challenges ...

Power of Process Improvement: The Electronics Industry

While Achieving 6 Sigma Quality

Performance & Quality Improvements
More Powerful & Reliable Devices
Tremendous Consumer Value
The Auto Industry Challenges Drove Quality Improvements

- Planned obsolescence
- New competition
- Loss of market share
- Improved product quality

... But ...

If the auto industry had achieved similar improvements in the last 30 years...

... a Rolls Royce would cost only $50

... it would circle the globe twice on only 0.5 gallons of gas

... its top speed would be 2.5 million mph!

Source: ICE Cost Effective IC Manufacturing
### So Why Have Pharmaceuticals Not Achieved 6 Sigma Manufacturing?

<table>
<thead>
<tr>
<th>Sigma</th>
<th>ppm Defects</th>
<th>Yield</th>
</tr>
</thead>
<tbody>
<tr>
<td>2σ</td>
<td>308,537</td>
<td>69.2%</td>
</tr>
<tr>
<td>3σ</td>
<td>66,807</td>
<td>93.3%</td>
</tr>
<tr>
<td>4σ</td>
<td>6,210</td>
<td>99.4%</td>
</tr>
<tr>
<td>5σ</td>
<td>233</td>
<td>99.98%</td>
</tr>
<tr>
<td>6σ</td>
<td>3.4</td>
<td>99.99966%</td>
</tr>
</tbody>
</table>

“We achieve 6 sigma quality using 3 sigma processes”

“Quality is free at the end of the day, if you can get it right”

Source: PriceWaterhouseCoopers Presentation, FDA Science Board Meeting November 16, 2001
What Keeps us from Changing

- Victims of our own success
- Products have strong patent protection
- We are isolated from economic cycles
- Regulatory systems promoted and encouraged an inspect and test quality system

There has not been sufficient pain creating pressure to force us to change!

Is the Perfect Storm Brewing?

<table>
<thead>
<tr>
<th>Electronics Industry Dynamics</th>
<th>Bio &amp; Pharm Similarities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extreme cost pressures</td>
<td>Health Care Cost Concerns</td>
</tr>
<tr>
<td>Easy to copy</td>
<td>Look-a-Likes</td>
</tr>
<tr>
<td>Material Costs</td>
<td>Capital Intensive</td>
</tr>
<tr>
<td>Reliability</td>
<td>Safety</td>
</tr>
</tbody>
</table>

A major storm is around the corner. Successful companies will batten down the hatches today to weather the storm tomorrow.
Agenda

- What is CAPA?
- Other Industries
- Case Study: How CAPA developed in Biotech
  - The Desired State
  - Enablers for an Effective CAPA System
  - Lessons Learned
- Summary

Stuff Happens

How we deal with issues will make or break us! A robust CAPA process will help make good decisions easier!
The CAPA Journey Provides Many Lessons Learned

1. Prior to 1995
   - Deviation Reports
     - Report only major departures from procedure

2. 1995 to 2001
   - Quality Incidents
     - Expand scope to include more types of discrepancies

3. 2001 to 2006
   - Non-conformances
     - Expand scope; emphasize investigation quality; little risk management

4. Overwhelmed the System with Numbers

5. Management Review & Quality Plan

6. Risk Based Approach Implemented

7. Today
   - Non-conformances
     - Risk based, Strong Governance with action oriented management review
   - More trending & holistic review of data identifying preventive actions

Basics of Today’s CAPA System

- Today the majority of CAPAs start with exceptions and are “Manufacturing Focused”
  - Deviations, Non-Conformances, Annual Product Review, Management Review, Complaints, Risk Management, Validation, etc

- Patient focused
  - Risk based
  - Effort, resources and timelines proportional to patient risk
Basics of Today’s CAPA System

- Strong Governance
  - Vet appropriateness of corrective actions and timelines

- Management Review
  - Defined metrics plan
  - Escalation process
  - Management commitment

Agenda

- What is CAPA?
- Other Industries
- Case Study: How CAPA developed in Biotech

- The Desired State
- Enablers for an Effective CAPA System
- Lessons Learned
- Summary
ICH Q10 Recommends a Product Lifecycle Approach

Table II: Application of Corrective Action and Preventive Action System Throughout the Product Lifecycle

<table>
<thead>
<tr>
<th>Pharmaceutical Development</th>
<th>Technology Transfer</th>
<th>Commercial Manufacturing</th>
<th>Product Discontinuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product or process variability is explored. CAPA methodology is useful where corrective actions and preventive actions are incorporated into the iterative design and development process.</td>
<td>CAPA can be used as an effective system for feedback, feedforward, and continual improvement.</td>
<td>CAPA should be used, and the effectiveness of the actions should be evaluated.</td>
<td>CAPA should continue after the product is discontinued. The impact on product remaining on the market should be considered, as well as other products that might be affected.</td>
</tr>
</tbody>
</table>

The Future

- More CAPAs will be based on non-exception type data such as:
  - Data trending and holistic data reviews
  - Continuous Improvement Projects
  - Industry and Regulatory Surveillance
  - Cost of Quality Model
  - Implement CAPA earlier in the development process
ICH Q10 Require that Management have a formal process for reviewing the QS ... 

The review should include:

(a) Measurement of achievement of pharmaceutical quality system objectives

(b) Assessment of performance indicators that can be used to monitor the effectiveness of processes within the pharmaceutical quality system, such as:

(1) Complaint, deviation, CAPA & change management...

Management Support and Management Review are Critical for an Effective CAPA Process.
Don’t Forget that You Also Need

- Robust business process
- Standard methodology
- Information system
- Effective Training

Agenda

- What is CAPA
- Other Industries
- Case Study
  How CAPA developed in Biotech
- The Desired State
- Enablers for an Effective CAPA System
- Lessons Learned
- Summary
Lessons Learned

Law of Unintended Consequences

- Numbers can overwhelm → Risk Based
- Artificial timelines → Realistic dates & interim reports
- Metrics & bad behaviors → Choose right metrics

These three unintended consequences are the major reasons that CAPA systems have failed.

Lessons Learned

- Use a systematic approach
  - Have a standard tool
  - But choose the right tool for the job

- Monitor metrics closely (Management Review)
  - Only need a few critical metrics
  - Keep metrics simple
  - Use metrics to drive the right behaviors
  - Build in checks and balances

- Strong governance
Our Performance Metrics Greatly Improved

- Management Review Identified gaps
- Redeployed the best resources
- Quality and timeliness improved
- Faster root cause identification leading to more effective corrective & preventive actions
- Fewer significant & repetitive deviations

Investigation and CAPA performance significantly improved

Agenda

- What is CAPA
- Other Industries
- Case Study
  - How CAPA developed in Biotech
- The Desired State
- Enablers
- Lessons Learned
- Summary
Summary

- Remember stuff will and does happen
- CAPA is an extremely valuable tool for continuous improvement
- Implement risk management and focus on the important issues first
- As professionals we should strive to prevent significant problems
- Use metrics to monitor performance
- Beware of unintended consequences

Thank You

Martin VanTrieste, R.Ph.
SVP of Quality
Amgen Inc
One Amgen Center
Mail Stop 92-D-2
Thousand Oaks, Ca 91320-1799
mvantrie@amgen.com